BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37344491)

  • 21. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings.
    Purysko AS; Magi-Galluzzi C; Mian OY; Sittenfeld S; Davicioni E; du Plessis M; Buerki C; Bullen J; Li L; Madabhushi A; Stephenson A; Klein EA
    Eur Radiol; 2019 Sep; 29(9):4861-4870. PubMed ID: 30847589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 27. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Pockros B; Stensland KD; Parries M; Frankenberger E; Canes D; Moinzadeh A
    Prostate; 2022 Feb; 82(3):352-358. PubMed ID: 34878175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Visible Tumor (PI-RADS ≥ 3) on Upgrading and Adverse Pathology at Radical Prostatectomy in Low Risk Prostate Cancer Patients: A Biopsy Core Based Analysis.
    Özkan A; Köseoğlu E; Kılıç M; Baydar DE; Sağlıcan Y; Balbay MD; Canda AE; Kordan Y; Kiremit MC; Çil B; Tuğcu V; Bakır B; Esen T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e61-e67. PubMed ID: 34750082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: Most New Disagreement Stems from Scores 1 and 2.
    Beetz NL; Haas M; Baur A; Konietschke F; Roy A; Hamm CA; Rudolph MM; Shnayien S; Hamm B; Cash H; Asbach P; Penzkofer T
    Rofo; 2022 Aug; 194(8):852-861. PubMed ID: 35545106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI.
    Chung DY; Koh DH; Goh HJ; Kim MS; Lee JS; Jang WS; Choi YD
    BMC Cancer; 2018 Nov; 18(1):1057. PubMed ID: 30382916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
    Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
    Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.
    Linhares Moreira AS; De Visschere P; Van Praet C; Villeirs G
    Acta Radiol; 2021 Jun; 62(6):839-847. PubMed ID: 32702998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 40. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.